Nipro operations note: i-almost-bought-the-cheapest-catheterthen-i-did-the-math-33

Back in late 2023, I sat down to plan our Q1 2024 procurement for the renal center. I'd been managing our supply budget for about six years by then, and I thought I had the process down cold. I'd saved us roughly 17% the year before by switching vendors on a few high-volume lines. I felt good about it.

Thing is, that 17% savings I was so proud of? It had come from negotiating hard on unit price. I chased the lowest sticker price like it was the whole game. I didn't fully appreciate the hidden costs until a specific experience with a different product taught me a lesson I won't forget.

The Setup: Looking at Nipro's Offerings

One of the recurring items on my list was a specific type of consumable for our dialysis equipment. We'd been sourcing them from a competitor, but I'd heard good things about Nipro medical's supply chain reliability. Specifically, I wanted to look at their catheter product line to evaluate as a potential alternative for a new clinic we were opening.

I pulled quotes from three vendors. Vendor A offered Nipro's catheters at $2.85 per unit. Vendor B, the incumbent, quoted $3.10. Vendor C, a smaller distributor, offered a non-branded alternative at $2.35.

My initial reaction was, “Easy. Vendor C saves us 15 bucks a box.” I was ready to pull the trigger.

The First Red Flag

Then I stopped. Something about the Nipro pricing bugged me. I talked to a colleague who'd worked with them before. He asked a question I'd never thought to ask: “Does that $2.85 include the introducer and the stabilization kit?”

Turns out, it didn't. The Nipro quote was for the catheter alone. Vendor B's $3.10 included the full insertion kit. Vendor C's $2.35 was also just the catheter, and they charged a flat $50 fee per order for “standard packaging consolidation.”

That's the moment I realized I wasn't comparing apples to apples. I was comparing a single fruit to a fruit salad.

The TCO Breakdown

I built a quick spreadsheet. For a quarterly order of 600 units (50 boxes of 12), here's what the real numbers looked like:

• Vendor C (Non-branded, cheapest unit price): $2.35/unit × 600 = $1,410. Plus the $50 packaging consolidation fee. Plus I'd need to source the introducers separately from another vendor, which added $3.20 per unit. Total: $1,410 + $50 + $1,920 = $3,380
• Vendor B (Incumbent, higher unit price): $3.10/unit × 600 = $1,860. Inclusive of everything. But their lead time was consistently 14 business days, and we'd had two instances of backorders in the past year. Risky.
• Vendor A (Nipro, mid-range quote): $2.85/unit × 600 = $1,710 for the catheter. Then I had to add the stabilization kit: $0.75/unit. The introducer was included in their “procedure pack” option. That pack was $3.65/unit all-in. Total: $2,190

Wait, the math didn't work. The Nipro all-in kit quote I got later was $3.65? Yes. That's $2,190 quarterly. That's $1,190 more than Vendor C's sticker price for the catheter alone.

But hold on. Let's look at the TCO properly.

Vendor C's $3,380 didn't include the cost of my staff's time spent managing two purchase orders, storing two separate inventory lines, and the risk of stock mismatches. It also didn't factor in the clinical risk of using a non-branded introducer that might not perfectly interface with our dialysis machines. My head of nursing told me she'd had a bad experience with a third-party introducer that kinked during a procedure. The cost of that single incident—wasted supplies and a rescheduled patient—was enough to wipe out any savings for a month.

The Moment of Fear

Here's where I share something I'm not proud of. I almost went with Vendor C anyway. The budget pressure was real. Our CFO had asked us to cut supply costs by 8% for 2024. The $2.35 price was just so tempting.

I can still feel the hesitation. The numbers on the spreadsheet were telling me one thing, but the single unit price was whispering in my ear. It's a cognitive trap I fell into before.

“Most buyers focus on per-unit pricing and completely miss setup fees, revision costs, and shipping that can add 30-50% to the total.”

In my first year, I made the classic specification error: assumed 'standard kit' meant the same thing to every vendor. Cost me a $600 redo when we had to expedite a missing component. That was a rookie mistake. I didn't want to repeat it.

Why I Chose Nipro

I eventually went with Vendor A and the Nipro all-in kit. The TCO, when measured properly, showed that the $2,190 quote was actually the most predictable and safe option. Here's the breakdown I presented to my CFO:

• Predictability: One SKU, one purchase order, one delivery. Total cost: $2,190. No surprises.
• Quality Assurance: Nipro's catheter and introducer are designed to work together. It reduced a clinical risk that we couldn't quantify easily.
• Nipro's Support: Their rep provided in-service training for our new nurses, which I didn't factor into the TCO but was a real value add.

Vendor B could've won if they'd offered the Nipro kit, but their service levels for the previous year had been spotty. The guaranteed turnaround from Nipro's US distribution center tipped the scales. To be fair, Vendor B's pricing was competitive for what they offered, but the uncertainty of their lead time counted against them.

The Real Lesson

What did I learn? The cost of the cheapest option wasn't $2.35. It was the $3,380 total plus the unquantified risk of a procedure issue. The Nipro option, at $2,190 total, was the actual lowest cost when I accounted for everything.

That's the thing about procurement in a field like this. You can't just be a number-cruncher. You have to understand the clinical context, the supply chain reality, and the hidden costs of complexity.

Since that Q1 2024 decision, I've built a TCO calculator that we use for every new product category. It's saved us from making the wrong call more than once. If there's one piece of advice I'd give, it's this: The question everyone asks is 'what's your best price?' The question they should ask is 'what's included in that price?'

Don't hold me to this, but I figure the Nipro decision saved us from at least one expensive clinical incident, which would've been a problem far bigger than any spreadsheet could handle.